https://theunj.org/issue/feed 2025-03-05T09:51:11+02:00 Vadym Biloshytsky unj.office@gmail.com Open Journal Systems <p><strong>The Ukrainian Neurosurgical Journal</strong> is a peer-reviewed open access medical journal.</p> <p>Published since 1995.<br /><br />Previous Titles:<br />Bûleten' Ukraïns'koï Asociaciï Nejrohirurgiv = Byulleten' Ukrainskoj Associacii Nejroxirurgov = Bulletin of the Ukrainian Association of Neurosurgeons (1995-1999)<br />Ukraïns'kij nejrohìrurgìčnij žurnal = Ukrainskij nejrohirurgičeskij žurnal = Ukrainian Neurosurgical Journal (2000-2018) • ISSN (Print): 1810-3154, ISSN (Online): 2412-8791<br /><br />In 2019, the Journal was re-registered with the only name of the Ukrainian Neurosurgical Journal • ISSN (Print): 2663-9084, ISSN (Online): 2663-9092.</p> <p><strong>Focus and Scope</strong><br />Ukrainian Neurosurgical Journal is covering basic and clinical researches on neurosurgery, including neuroradiology, otoneurology, clinical neurophysiology, organic neurology, neuroimmunology, neurochemistry, and neuropathology; publishes issues of public health organization in the field of neurosurgery.</p> <p><strong>Founders</strong><br /><a href="https://neuro.kiev.ua/en/main-page-2/" target="_blank" rel="noopener">Romodanov Neurosurgery Institute</a><br /><a href="https://www.uaneuro.com/en" target="_blank" rel="noopener">Ukrainian Association of Neurosurgeons</a><br /><a href="https://amnu.gov.ua/" target="_blank" rel="noopener">National Academy of Medical Sciences of Ukraine</a></p> <p><strong>Publisher:</strong> <a href="https://neuro.kiev.ua/en/category/for-professionals-en/publishing-en/" target="_blank" rel="noopener">Romodanov Neurosurgery Institute</a></p> <p><strong>Language:</strong> Ukrainian, English</p> <p><strong>Frequency:</strong> Quarterly</p> <p><strong>Registration in the Ministry of Education and Science of Ukraine:</strong> In accordance with the Procedure for the Formation of the Scientific Journal List of Ukraine, Ukrainian Neurosurgical Journal is assigned category "A" (the Ministry of Education and Science of Ukraine Order No 1721 dated 10 December 2024.</p> https://theunj.org/article/view/313858 2024-10-22T11:46:42+03:00 Vadym V. Biloshytsky dr.biloshytsky@spravno.clinic Maryna V. Biloshytska m.biloshytska@gmail.com Anatolii I. Gavretskyi Erty2204@ukr.net Dmytro V. Dmytriiev dmytrodmytriiev@gmail.com Roman Cregg drcregg@gmail.com Andrii B. Medytskyi Medytskyy@gmail.com Volodymyr I. Romanenko vr@pain.ua Yanosh Y. Sanotskyy sanotsky@gmail.com Nadiya T. Segin Nadiyasegin@gmail.com Lyudmyla V. Fedoryshyn ljuda_fed@yahoo.com Andrii V. Filipskyi andriyfilipskiy91@gmail.com Kateryna V. Chekha Chekha.doc@gmail.com

<p><strong>Background</strong>: Neuropathic pain is a condition of complex nature arising from damage to or dysfunction of the sensory nervous system. Conventional treatment options (like antidepressants, anticonvulsants, and opioids) frequently have limited efficacy and substantial side effects. Thereat, increasing attention is being paid to botulinum toxin therapy (BTT) as a promising option for the treatment of neuropathic pain.</p> <p><strong>Purpose</strong>: To develop the Ukrainian national consensus statement on the use of botulinum neurotoxin (BoNT) to treat neuropathic pain through the review of available literature, compilation of experience of Ukrainian specialists, and formulation of relevant practical recommendations.</p> <p><strong>Methods</strong>: Our working group reviewed the current literature (including randomized clinical trials, systematic reviews and meta-analyses) and personal clinical observations related to the use of BoNT to treat painful neuropathic syndromes.</p> <p><strong>Results</strong>: BoNT demonstrated high efficacy in the treatment of neuropathic pain, particularly in postherpetic neuralgia, painful diabetic neuropathy, trigeminal neuralgia, post-amputation pain, trauma sequelae, spinal cord injury and other conditions. Its major pain relief mechanisms include modulation of neuronal activity, blocking the release of pain neuromediators, and neuroplastic effects. The optimal dosage amount was found to vary from 50 to 300 units, depending on the affected area, with mostly subcutaneous or intradermal BoNT injections used.</p> <p><strong>Conclusion</strong>: BTT is a safe promising treatment option for neuropathic pain and can be used either alone or in combination with other pain relief modalities. Our working group developed practical recommendations on BoNT indications, doses and injection techniques in painful neuropathic syndromes which can be implemented into clinical practice to improve patients’ quality of life.</p>

2025-03-05T00:00:00+02:00 Copyright (c) 2025 Вадим В. Білошицький, Марина В. Білошицька, Анатолій І. Гаврецький, Дмитро В. Дмитрієв, Роман Крегг, Андрій Б. Медицький, Володимир І. Романенко, Янош Є. Саноцький, Надія Т. Сегін, Людмила В. Федоришин, Андрій В. Філіпський, Катерина В. Чеха